BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 20420175)

  • 1. [Paraneoplastic cerebellar degeneration].
    Sakai K
    Brain Nerve; 2010 Apr; 62(4):357-64. PubMed ID: 20420175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological Bases of Paraneoplastic Cerebellar Degeneration and Therapeutic Implications.
    Yshii L; Bost C; Liblau R
    Front Immunol; 2020; 11():991. PubMed ID: 32655545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Importance of plasmapheresis in the treatment of paraneoplastic cerebellar degeneration].
    Basić-Jukić N; Kes P; Basić-Kes V; Brunetta B
    Acta Med Croatica; 2004; 58(1):63-6. PubMed ID: 15125396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Ri-associated paraneoplastic cerebellar degeneration without opsoclonus in a patient with a neuroendocrine carcinoma of the stomach.
    Kikuchi H; Yamada T; Okayama A; Hara H; Taniwaki T; Shigeto H; Sasaki M; Iwaki T; Kira J
    Fukuoka Igaku Zasshi; 2000 Apr; 91(4):104-9. PubMed ID: 10826224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A study on pathomechanisms of paraneoplastic neurological syndrome].
    Tanaka K
    Rinsho Shinkeigaku; 2001 Dec; 41(12):1150-2. PubMed ID: 12235823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of cytotoxic T lymphocytes specific for paraneoplastic cerebellar degeneration-associated antigen in vivo by DNA immunization.
    Sakai K; Shirakawa T; Kitagawa Y; Li Y; Hirose G
    J Autoimmun; 2001 Dec; 17(4):297-302. PubMed ID: 11771954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure to detect cytotoxic T cell activity against recombinant Yo protein using autologous dendritic cells as the target in a patient with paraneoplastic cerebellar degeneration and anti-Yo antibody.
    Tanaka M; Tanaka K; Idezuka J; Tsuji S
    Exp Neurol; 1998 Apr; 150(2):337-8. PubMed ID: 9527904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Paraneoplastic cerebellar degeneration].
    Chabriat H; Chen QM; Poisson M; Delattre JY
    Rev Neurol (Paris); 1994; 150(2):105-14. PubMed ID: 7863150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphological and immunohistochemical characterization of paraneoplastic cerebellar degeneration associated with Yo antibodies.
    Storstein A; Krossnes BK; Vedeler CA
    Acta Neurol Scand; 2009 Jul; 120(1):64-7. PubMed ID: 19486326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome.
    Fukuda T; Motomura M; Nakao Y; Shiraishi H; Yoshimura T; Iwanaga K; Tsujihata M; Eguchi K
    Ann Neurol; 2003 Jan; 53(1):21-8. PubMed ID: 12509844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paraneoplastic antibodies detected by isoelectric focusing of cerebrospinal fluid and serum.
    Storstein A; Monstad SE; Honnorat J; Vedeler CA
    J Neuroimmunol; 2004 Oct; 155(1-2):150-4. PubMed ID: 15342206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients.
    Shams'ili S; Grefkens J; de Leeuw B; van den Bent M; Hooijkaas H; van der Holt B; Vecht C; Sillevis Smitt P
    Brain; 2003 Jun; 126(Pt 6):1409-18. PubMed ID: 12764061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paraneoplastic Cerebellar Degeneration With P/Q-VGCC vs Yo Autoantibodies.
    Winklehner M; Bauer J; Endmayr V; Schwaiger C; Ricken G; Motomura M; Yoshimura S; Shintaku H; Ishikawa K; Tsuura Y; Iizuka T; Yokota T; Irioka T; Höftberger R
    Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 36070310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Ri-associated paraneoplastic cerebellar degeneration and breast cancer: an autopsy case study.
    Brieva-Ruíz L; Diaz-Hurtado M; Matias-Guiu X; Márquez-Medina D; Tarragona J; Graus F
    Clin Neurol Neurosurg; 2008 Dec; 110(10):1044-6. PubMed ID: 18701208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pathogenesis of paraneoplastic neurological syndromes].
    Tanaka K
    Brain Nerve; 2010 Apr; 62(4):309-18. PubMed ID: 20420170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Paraneoplastic cerebral syndromes with oto-neuro-ophthalomologic manifestations].
    Dalmau J; Porta-Etessam J
    Rev Neurol; 2000 Dec 16-31; 31(12):1213-9. PubMed ID: 11205562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deterioration of anti-Yo-associated paraneoplastic cerebellar degeneration.
    Finsterer J; Voigtländer T; Grisold W
    J Neurol Sci; 2011 Sep; 308(1-2):139-41. PubMed ID: 21762925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An interferon-gamma ELISPOT and immunohistochemical investigation of cytotoxic T lymphocyte-mediated tumour immunity in patients with paraneoplastic cerebellar degeneration and anti-Yo antibodies.
    Sutton IJ; Steele J; Savage CO; Winer JB; Young LS
    J Neuroimmunol; 2004 May; 150(1-2):98-106. PubMed ID: 15081253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy.
    Sillevis Smitt P; Grefkens J; de Leeuw B; van den Bent M; van Putten W; Hooijkaas H; Vecht C
    J Neurol; 2002 Jun; 249(6):745-53. PubMed ID: 12111309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Autoantibodies associated with autoimmune-mediated cerebellar ataxia].
    Mitoma H; Nanri K
    Brain Nerve; 2013 Apr; 65(4):355-64. PubMed ID: 23568983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.